摘要
目的研究分析糖类抗原125(CA125)结合人附睾分泌蛋白4(HE4)检验诊断卵巢癌的价值。方法选取2019年1月—2022年3月在扬州市江都人民医院治疗的60例卵巢癌患者设为研究组,选取同期收治的60例卵巢良性肿瘤患者设为对照组。对两组患者CA125、HE4水平进行检测,统计对比检测结果。结果研究组患者CA125、HE4水平均高于对照组患者,差异有统计学意义(P<0.05)。在研究组中,Ⅲ~Ⅳ期患者CA125、HE4水平均高于Ⅰ~Ⅱ期患者,差异有统计学意义(P<0.05)。在研究组中,有淋巴转移患者CA125、HE4水平分别为(412.03±86.59)kU/L、(372.36±86.75)pmol/L,均高于无淋巴转移患者,差异有统计学意义(t=15.046、7.636,P<0.05)。CA125结合HE4诊断卵巢癌的特异度、灵敏度、准确度、阴性预测值、阳性预测值均高于CA125与HE4单项诊断,差异有统计学意义(P<0.05)。结论在卵巢癌诊断中,CA125结合HE4检验的临床价值更高,能够精准判定患者病情,为患者治疗提供指导依据。
Objective To study and analyze the value of carbohydrate antigen 125(CA125)combined with human epi⁃didymal secretory protein 4(HE4)test for the diagnosis of ovarian cancer.Methods From January 2019 to March 2022,60 patients with ovarian cancer treated in Yangzhou Jiangdu People's Hospital were selected as the study group,and 60 patients with benign ovarian tumors admitted in the same period were selected as the control group.The levels of CA125 and HE4 in the two groups were detected,and the results were statistically compared.Results The levels of CA125 and HE4 in the study group were higher than those in the control group,and the difference was statistically sig⁃nificant(P<0.05).In the study group,the levels of CA125 and HE4 in patients with stageⅢ-Ⅳwere higher than those in patients with stageⅠ-Ⅱ,and the difference was statistically significant(P<0.05).In the study group,the levels of CA125 and HE4 in patients with lymph node metastasis were(412.03±86.59)kU/L and(372.36±86.75)pmol/L,re⁃spectively,which were higher than those in patients without lymph node metastasis,and the difference was statistically significant(t=15.046,7.636,P<0.05).The specificity,sensitivity,accuracy,negative predictive value and positive pre⁃dictive value of CA125 combined with HE4 in the diagnosis of ovarian cancer were higher than those of CA125 and HE4 alone,and the difference was statistically significant(P<0.05).Conclusion In the diagnosis of ovarian cancer,the clinical value of CA125 combined with HE4 test is higher,which can accurately determine the patient's condition and provide guidance basis for patient treatment,and is worthy of clinical recommendation and application.
作者
邵大祥
李绪文
SHAO Daxiang;LI Xuwen(Department of Laboratory,Yangzhou Jiangdu People's Hospital,Yangzhou,Jiangsu Province,225200 China)
出处
《系统医学》
2023年第1期10-14,共5页
Systems Medicine
关键词
卵巢癌
糖类抗原125
人附睾分泌蛋白4
诊断价值
Ovarian cancer
Carbohydrate antigen 125
Human epithelial secretory protein 4
Diagnostic value